Our shared concern:
Sepsis management
Every 2.8 seconds, someone dies from sepsis1
1/17 hospitalized patients have sepsis2
The average US cost of a hospital stay for sepsis patients is double that for other conditions3
It’s all about time. The risk of death from sepsis goes up 9% for every hour of delay in appropriate antibiotic treatment.3
Empower your lab, clinicians and institution with a fast, integrated approach to sepsis management.
bioMérieux understands the specific challenges for timely, appropriate sepsis management.
That’s why we’ve brought together the market’s only integrated SEPSIS SOLUTION covering the entire diagnostic pathway to impact therapy from initiation, to optimization, to discontinuation.
1. Global Report on the Epidemiology and Burden of Sepsis, World Health Organization, 2020, https://www.who.int/news/item/08-09-2020-who-calls-for-global-action-on-sepsis---cause-of-1-in-5-deaths-worldwide
2. https://www.hcup-us.ahrq.gov/reports/statbriefs/sb168-Hospital-Costs-United-States-2011.jsp
3. Liu VX et al., American Journal of Respiratory and Critical Care Medicine, 2017
BURDEN OF SEPSIS
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection.
Every hour of delay in giving appropriate antibiotics increases
mortality by 9%3
Every 2.8 seconds
someone dies from sepsis4
> 40% of all cases
occurring in children under 52
1 in 3 people
who die in a hospital had sepsis during that hospitalization3
$62b
estimated annual cost for US hospitalizations4
1.7m
cases of sepsis among US adults each year3
It’s all about time:
The impact of fast diagnostics
Sepsis is a complex and challenging condition to manage for medical teams
With 3 main challenges
Non exclusive symptoms
Making sepsis difficult to recognize among other conditions
Unavailable or delayed information5,6
With an average of 3 days to a complete analysis from blood culture, increasing risk of inadequate therapy or overtreatment
Complex proess from multidisciplinary teams
Establish effective collaboration with nurses, pharmacists, laboratories staff, etc.
The longer it takes to administer the right treatment, the lower the survival rate3
Clinicians must initiate antimicrobial therapy as early as possible
of patients receive inapropriate therapy7,8,9
The role of microbiology lab
is key to reduce the time needed
to administer the appropriate treatment
4. Rudd E, The Lancet Infectious Diseases, 2020
5. Rhee C et al. JAMA Network Open. 2020;3(4):e202899;
6. Sweeney TE et al. Expert Review of Molecular Diagnostics 2019, VOL. 19, NO. 11, 959–962
7. Schuttevaer R, et al. PLoS One, 2019
8. Baltas I, et al. J Antimicrob Chemother. 2021
9. Kadri SS, et al. The Lancet Infectious Diseases, 2021
Bloodstream infection diagnostics,
benefits of the bundled approach
Although any infection can lead to sepsis, more than 40% of patients with a bloodstream infection develop sepsis. Blood culture remains the gold standard for diagnosing sepsis.10,11
Bloodstream Infections
42% patients9
Sepsis
42% patients9
Septic shock
80% of sepsis deaths could be prevented by
quicker diagnosis and treatment12
10. Duncan CF et al., Curr Infect Dis Rep, 2021
11. Sinha M et al., Clin Microbiol Rev, 2018
12. Sepsis Alliance. Sepsis fact sheet, 2022
“Progress in BSI pathogen diagnostics is based on a bundle approach that includes optimization of the pre-analytical parameters, rapid start of incubation, the use of rapid methods, re-organization (e.g. 24/7, transportation service) and a close involvement of antimicrobial stewardship teams. These developments lead to define a new standard for bloodstream infection diagnostics.”13
13. Lamy B., et al.: “Bloodstream infections - Standard and progress in pathogen diagnostics”. Clin Microbiol Infect. 2020 Feb; 26
Bundle approach
based on 3 main recommendations
bioMérieux has you covered:
A worrisome link:
Sepsis and antimicrobial resistance
Antimicrobial resistance is a key concern in cases of sepsis. Empirical therapy – typically implemented prior to diagnostics-driven therapy optimization – carries risks for unnecessary broad-spectrum treatment or incorrect treatment, which are associated with increased potential for development of antimicrobial resistance.
Sepsis patients with infections caused by resistant organisms are the most difficult to treat and have the highest risk of mortality14. As more resistant bacteria emerge, the arsenal of effective antibiotic treatments for sepsis is reduced.
14. Singer M, Deutschman CS, Seymour CW, et al: The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315:801-810
Reduce the burden of sepsis in your institution
bioMérieux is your partner of choice for sepsis management. Impact patient outcomes for sepsis and experience key benefits for your institution.
Using a diagnostic technique to manage BSI early PROVIDES
Reduction
on mortality15,16
Reduced length of stay readmission rate and complications17
Decreased broad-spectrum antibiotic consumption and associated costs18
Efficient monitoring of nosocomial infections and MDRO
15.Timbrook et al., Clinical Infectious Diseases, 2016
16.Senok A, et al., Diagnostics, 2023
17.De La Villa et al. Journal of Antimicrobial Chemotherapy, 2023
18.Britt NS, et al. Pharmacotherapy, 2023
Designed by Freepik
Discover bioMérieux
integrated SEPSIS SOLUTION
How can bioMérieux’s fast, integrated SEPSIS SOLUTION enable bloodstream infection diagnostic results in just 24 hours, compared to
60 hours or more with traditional methods?
COST EFFECTIVENESS ANALYSIS POSTER
BACT/ALERT® VIRTUO®
Detects 8.7 hours earlier in aerobic blood culture bottles from patients already on patients already on antimicrobial treatment19
BIOFIRE® BCID2 Panel
Provides ID and AMR genes results in ~1 hour, decreasing the time to optimal therapy20-23
VITEK® REVEAL™
Enables fast targeted therapy with phenotypic AST results in an average of 5.5-6h, 18h earlier than traditional AST for blood culture24-27
MAESTRIA™ / CLARION™
Integrate diagnostics results and transform your data into relevant actionable healthcare insights
19. Halperin A, et al. Microbiology spectrum vol. 10,5 (2022)
20. Chiasson J, et al. J Pharm Prac. 2021; 35(5):722-729
21. Verroken A., et al. (2019). PLOS ONE: 14(9): e0223122
22. MacVane S and Note F. J Clin Microbiol. 2016 Oct;54(10):2455-63.
23. Banerjee R et al. Clin Infect Dis 2015;61:1071-80.
24. Rottman M, et al. ECCMID 2022.
25. BMX. 1. 129899 Clinical Trial Summary Report (proprietary, on file at bioMérieux).
26. Yuceel-Timur I, et al. ECCMID 2023
27. Gastli N, et al. ECCMID 2023
* The 24 hour window for results is a calculated value based on instrument run time.
